Why Breakthrough Therapies in Biotech Are Losing the Commercial Battle
Summary
The biotech industry is developing advanced therapies like personalized cancer treatments and gene therapies, but many companies struggle to succeed commercially after getting regulatory approval. Industry experts say strong planning and teamwork are needed to turn scientific breakthroughs into profitable products.Key Facts
- New biotech treatments, such as Zi-MA4-1 cancer therapy and new gene/cell therapies, have been approved recently.
- Developing a new medicine can cost more than $2 billion due to research and testing.
- Regulatory approval does not guarantee a therapy will sell well or be widely used.
- Companies must build market demand, educate doctors, and develop sales teams to succeed.
- Investors now expect biotech firms to show solid business plans and growth after approval.
- Commercial skills and infrastructure are becoming as important as scientific innovation.
- Amy Vie, a pharmaceutical executive, says companies often fail because they do not effectively execute their plans.
- Vie emphasizes building trust and teamwork within companies to improve performance and growth.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
